my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-31-2012: Merck Millipore and Proteomics International announced a collaboration to validate biomarkers related to diabetic nephropathy (kidney disease). Diabetic nephropathy is a significant complication of diabetes; of the 280 million people affected by diabetes worldwide, 10-20% are expected to die of kidney failure.
Under the collaboration, Proteomics International will assess its thirteen newly identified putative protein biomarkers by using Merck Millipore’s multiplex immunoassays. The biomarkers include proteins involved in metabolism, inflammation, and oxidative stress. Once validated, the biomarkers could be used to monitor the progression and prognosis of kidney disease in patients with diabetes.
Currently, diabetic nephropathy is screened using the microalbumin test, a single biomarker in the urine that has limited utility, however, in predicting and monitoring disease progression. Several of the newly identified biomarkers show promise in enhancing the current screening methods by identifying a signature of biomarkers in the blood that can better represent disease prediction and progression. Proteomics International will also utilize its extensive sample repository of relevant clinical specimens to assess additional biomarkers developed by Merck Millipore.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Q1/2012: Merck Total Revenues Increase 3.2% to € 2.6 Billion
“Merck delivered a reasonable operating performance in the face of a difficult year-over-year comparison,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “During the first quarter, we kicked off our efficiency program and announced the first planned initiatives as part of ... more
Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit
Merck announced results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specif ... more
Merck Announces Merck Serono Implementation Plans for Its Efficiency Program in Switzerland
Merck announced the efficiency measures it plans to take related to Merck Serono’s operations in Switzerland as part of the comprehensive transformation program announced by the company in February. Merck’s transformation program is focused on addressing unprecedented market shifts, increas ... more
Pyrodetect System: the Human(e) Alternative in Pyrogen Testing
A revolutionary test for the detection and quantification of pyrogens based on the monocyte activation test (MAT) more
ISOSLIDE® Reticulin control slides for histology
The ISOSLIDE® Reticulin Control Slides Box is a new product from Merck Millipore for the detection of reticulin fibers in histological tissue specimen more
Merck Millipore offers new, user-friendly packaging sizes for its microscopy products Entellan® new, Schiff´s reagent and OSTEOMOLL® more
Merck Millipore provides all expertise on chromatography in one place
With almost 400 pages, the catalog contains detailed information on a total of around 4,000 Merck Millipore chromatography products more
The Merck Group is a globally operating company in the areas of pharmaceuticals and chemicals. With 34,500 employees and more than 200 companies we are represented in 58 countries worldwide. Founded in 1668 in Darmstadt, Germany, the company sees the keys to success in entrepreneurial emplo ... more
Merck Schuchardt OHG, a 100% subsidiary of Merck KGaA, Germany, has, for the last 135 years, been one of the leading German producers and suppliers of organic intermediates, fine chemicals, reagents and solvents for laboratories, medium-sized and bulk production. more
Together EMD Biosciences and Merck Chemicals Ltd. are the research reagents group of the Performance and Life Science Chemicals division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has more than 29,000 employees in 53 countries. EMD or Merck – why two names ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
